Alkermes plc (NASDAQ:ALKS) Receives $54.56 Average Target Price from Analysts

Posted by on Aug 10th, 2026

Shares of Alkermes plc (NASDAQ:ALKS – Get Free Report) have received a consensus rating of “Moderate Buy” from the eighteen brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $54.5625.

A number of brokerages recently issued reports on ALKS. Piper Sandler restated an “overweight” rating and issued a $65.00 target price (up from $43.00) on shares of Alkermes in a research note on Tuesday, July 28th. UBS Group boosted their price target on Alkermes from $42.00 to $48.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Mizuho increased their price objective on Alkermes from $53.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, July 2nd. Zacks Research upgraded Alkermes from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Bank of America reaffirmed an “underperform” rating on shares of Alkermes in a report on Monday, June 29th.

View Our Latest Analysis on Alkermes

Insider Buying and Selling at Alkermes

In other news, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $51.51, for a total value of $463,590.00. Following the sale, the executive vice president directly owned 73,389 shares of the company’s stock, valued at $3,780,267.39. This represents a 10.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Lynn Md Snyderman sold 44,472 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $50.35, for a total transaction of $2,239,165.20. Following the completion of the sale, the director directly owned 15,395 shares in the company, valued at $775,138.25. This trade represents a 74.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 79,574 shares of company stock valued at $3,901,478. 4.59% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALKS. Sanctuary Advisors LLC increased its holdings in Alkermes by 2.7% in the 4th quarter. Sanctuary Advisors LLC now owns 12,141 shares of the company’s stock worth $340,000 after acquiring an additional 315 shares in the last quarter. PNC Financial Services Group Inc. grew its position in shares of Alkermes by 3.5% in the fourth quarter. PNC Financial Services Group Inc. now owns 10,326 shares of the company’s stock valued at $289,000 after purchasing an additional 351 shares during the period. Versant Capital Management Inc grew its position in shares of Alkermes by 33.9% in the second quarter. Versant Capital Management Inc now owns 1,445 shares of the company’s stock valued at $76,000 after purchasing an additional 366 shares during the period. Orion Porfolio Solutions LLC increased its stake in shares of Alkermes by 4.5% during the third quarter. Orion Porfolio Solutions LLC now owns 8,762 shares of the company’s stock worth $263,000 after purchasing an additional 376 shares in the last quarter. Finally, Horizon Investments LLC increased its stake in shares of Alkermes by 0.9% during the third quarter. Horizon Investments LLC now owns 43,002 shares of the company’s stock worth $1,290,000 after purchasing an additional 387 shares in the last quarter. 95.21% of the stock is currently owned by institutional investors and hedge funds.

Alkermes Stock Performance

NASDAQ ALKS opened at $49.17 on Monday. The company has a fifty day simple moving average of $49.28 and a two-hundred day simple moving average of $38.88. The stock has a market cap of $8.25 billion, a P/E ratio of 129.40 and a beta of 0.34. Alkermes has a 12-month low of $25.17 and a 12-month high of $55.67. The company has a current ratio of 2.30, a quick ratio of 1.85 and a debt-to-equity ratio of 0.82.

Alkermes Company Profile

(Get Free Report)

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.

Featured Stories

Analyst Recommendations for Alkermes (NASDAQ:ALKS)

Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.